Literature DB >> 10794699

Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation.

S H Szajnman1, W Yan, B N Bailey, R Docampo, E Elhalem, J B Rodriguez.   

Abstract

As a part of our project directed at the search of new chemotherapeutic agents against American trypanosomiasis (Chagas' disease), several drugs possessing the 4-phenoxyphenoxy skeleton and other closely related structures employing the thiocyanate moiety as polar end group were designed, synthesized, and evaluated as antiproliferative agents against Trypanosoma cruzi, the parasite responsible for this disease. These thiocyanate analogues were envisioned bearing in mind the potent activity shown by 4-phenoxyphenoxyethyl thiocyanate (compound 8) taken as lead drug. This compound had previously proved to be an extremely active growth inhibitor against T. cruzi with IC(50) values ranging from the very low micromolar level in epimastigotes to the low nanomolar level in the intracellular form of the parasite. Of the designed compounds, the ethyl thiocyanate drugs connected to nonpolar skeletons, namely, arylthio, 2,4-dichlorophenoxy, ortho-substituted aryloxy, and 2-methyl-4-phenoxyphenoxy (compounds 15, 34, 47, 52, 72, respectively), were shown to be very potent antireplicative agents against T. cruzi. On the other hand, conformationally restricted analogues as well as branched derivatives at the aliphatic side chain were shown to be moderately active against T. cruzi growth. The biological activity of drugs bearing the thiocyanate group correlated quite well with the activity exhibited by their normal precursors, the tetrahydropyranyl ether derivatives, when bonded to the same nonpolar skeleton. Compounds having the tetrahydropyranyl moeity as polar end were proportionally much less active than sulfur-containing derivatives in all cases. Drugs 47 and 72 also resulted to be very active against the amastigote form of the parasite growing in myoblasts; however, they were slightly less active than the lead drug 8. On the other hand, compounds 34 and 52 were almost devoid of activity against myoblasts. Surprisingly, the dithio derivative 15 was toxic for myoblasts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794699     DOI: 10.1021/jm9905007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein.

Authors:  Maryanna E Lanning; Wenbo Yu; Jeremy L Yap; Jay Chauhan; Lijia Chen; Ellis Whiting; Lakshmi S Pidugu; Tyler Atkinson; Hala Bailey; Willy Li; Braden M Roth; Lauren Hynicka; Kirsty Chesko; Eric A Toth; Paul Shapiro; Alexander D MacKerell; Paul T Wilder; Steven Fletcher
Journal:  Eur J Med Chem       Date:  2016-02-04       Impact factor: 6.514

2.  Activity of Fluorine-Containing Analogues of WC-9 and Structurally Related Analogues against Two Intracellular Parasites: Trypanosoma cruzi and Toxoplasma gondii.

Authors:  María N Chao; Catherine Li; Melissa Storey; Bruno N Falcone; Sergio H Szajnman; Sergio M Bonesi; Roberto Docampo; Silvia N J Moreno; Juan B Rodriguez
Journal:  ChemMedChem       Date:  2016-11-25       Impact factor: 3.466

3.  Aryloxyethyl Thiocyanates Are Potent Growth Inhibitors of Trypanosoma cruzi and Toxoplasma gondii.

Authors:  María N Chao; Carolina Exeni Matiuzzi; Melissa Storey; Catherine Li; Sergio H Szajnman; Roberto Docampo; Silvia N J Moreno; Juan B Rodriguez
Journal:  ChemMedChem       Date:  2015-04-27       Impact factor: 3.466

4.  Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents.

Authors:  Pablo D Elicio; María N Chao; Melina Galizzi; Catherine Li; Sergio H Szajnman; Roberto Docampo; Silvia N J Moreno; Juan B Rodriguez
Journal:  Eur J Med Chem       Date:  2013-09-18       Impact factor: 6.514

5.  Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation.

Authors:  Guadalupe García Liñares; Santiago Gismondi; Nicolás Osa Codesido; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Bioorg Med Chem Lett       Date:  2007-07-13       Impact factor: 2.823

Review 6.  Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase.

Authors:  Hugo Cerecetto; Mercedes González
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.